Literature DB >> 16434065

Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat.

Jennifer L Taylor1, Christopher Bishop, Thomas Ullrich, Kenner C Rice, Paul D Walker.   

Abstract

Previous experiments have demonstrated that serotonin (5-HT) 2A receptor antagonists suppress hyperkinetic behaviors associated with dopamine (DA) D1 receptor supersensitivity in rats with 6-hydroxydopamine (6-OHDA) lesions. Since l-DOPA induced dyskinesia (LID) may be mediated by over-sensitive D1-mediated signaling, the present study examined the effects of the selective 5-HT2A antagonist M100907 on LID behaviors in DA-depleted rats. Adult male Sprague-Dawley rats with unilateral 6-OHDA lesions received daily l-DOPA treatments to produce dyskinetic behaviors as measured by abnormal involuntary movements (AIMs) testing. In these animals, M100907 (0.01, 0.1 or 1.0mg/kg, ip) given 30 min before l-DOPA did not alter the appearance or intensity of AIMs behaviors. Because l-DOPA induced AIMs in rats are dependent upon D1 and D2 receptor activation, a second study was performed to determine if M100907 could suppress D1- or D2-mediated rotational behaviors. Contralateral rotations induced by the D1 agonist SKF82958 were significantly reduced by pre-treatment with M100907. However, M100907 was ineffective in reducing rotations induced by the D2 agonist quinpirole. The finding that M100907 suppresses rotations induced by D1, but not D2, agonists may provide a partial explanation for the lack of effect of a selective 5-HT2A antagonist on l-DOPA-induced AIMs behaviors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434065     DOI: 10.1016/j.neuropharm.2005.12.004

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  16 in total

1.  Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.

Authors:  Kristin B Dupre; Corinne Y Ostock; Karen L Eskow Jaunarajs; Thomas Button; Lisa M Savage; William Wolf; Christopher Bishop
Journal:  Exp Neurol       Date:  2011-02-22       Impact factor: 5.330

Review 2.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 3.  5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review.

Authors:  Cynthia Kwan; Imane Frouni; Dominique Bédard; Stephen G Nuara; Jim C Gourdon; Adjia Hamadjida; Philippe Huot
Journal:  Exp Brain Res       Date:  2018-11-15       Impact factor: 1.972

4.  5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.

Authors:  Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch; Twum A Ansah
Journal:  Neuropharmacology       Date:  2010-03-31       Impact factor: 5.250

Review 5.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

6.  Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Christopher J Barnum; Jessica A George; Margaret A Surrena; Christopher Bishop
Journal:  J Neurochem       Date:  2015-04-27       Impact factor: 5.372

7.  The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Christopher Bishop; S Paul Berger; Melanie A Paquette
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

8.  Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model.

Authors:  Andrew J Flores; Mitchell J Bartlett; Lisa Y So; Nicholas D Laude; Kate L Parent; Michael L Heien; Scott J Sherman; Torsten Falk
Journal:  Neurosci Lett       Date:  2014-02-11       Impact factor: 3.046

9.  Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.

Authors:  Kristin B Dupre; Karen L Eskow; Christopher J Barnum; Christopher Bishop
Journal:  Neuropharmacology       Date:  2008-09-10       Impact factor: 5.250

10.  Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice.

Authors:  Li Li; Guozhen Qiu; Shengyuan Ding; Fu-Ming Zhou
Journal:  Brain Res       Date:  2012-11-15       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.